Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

被引:192
作者
Burmester, Gerd-Rudiger [1 ]
Kivitz, Alan J. [2 ]
Kupper, Hartmut [3 ]
Arulmani, Udayasankar [4 ]
Florentinus, Stefan [5 ]
Goss, Sandra L. [4 ]
Rathmann, Suchitrita S. [4 ]
Fleischmann, Roy M. [6 ]
机构
[1] Charite, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany
[2] Altoona Ctr Clin Res, Duncansville, PA USA
[3] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany
[4] AbbVie Inc, N Chicago, IL USA
[5] AbbVie, Rungis, France
[6] Univ Texas Southwestern, Dallas, TX USA
关键词
RECEIVING CONCOMITANT METHOTREXATE; RHEUMATOID-ARTHRITIS; PLUS METHOTREXATE; MONOCLONAL-ANTIBODY; AMERICAN-COLLEGE; DOUBLE-BLIND; THERAPY; PHARMACOKINETICS; CLASSIFICATION; MONOTHERAPY;
D O I
10.1136/annrheumdis-2013-204769
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective CONCERTO was a randomised, double-blind, parallel-armed study of methotrexate (MTX) in combination with adalimumab to assess whether an increasing trend of efficacy and decreased safety exists when increasing MTX dose in patients with early rheumatoid arthritis (RA). Methods Early, biologic and MTX-naive RA patients (N=395) were evenly randomised to open-label adalimumab (40mg every other week) plus weekly blinded 2.5, 5, 10 or 20mg MTX for 26weeks. Clinical, radiographic and functional outcomes were analysed using two-sided linear trend tests or one-way analysis of covariance. Results Statistically significant increasing trends were observed in the proportion of patients achieving the primary endpoint, 28-joint count disease activity score with C reactive protein (DAS28(CRP)) <3.2 (42.9%, 44.0%, 56.6% and 60.2% for 2.5, 5, 10 or 20mg/week MTX, respectively), DAS28(CRP) <2.6 and American College of Rheumatology 50/70/90 responses with increasing doses of MTX in combination with adalimumab. No statistical differences in minimal clinically important differences in physical function were detected. Statistically significant trends for achieving low disease activity and remission were demonstrated with increasing MTX dose by validated clinical indices; differences comparing 10 and 20mg MTX were minimal. Adalimumab serum concentrations increased with ascending dose up to 10mg MTX. More patients experienced infectious adverse events with increasing MTX dose. Conclusions Increasing doses of MTX in combination with adalimumab demonstrated a statistically significant trend in improved clinical outcomes that mimicked the adalimumab pharmacokinetic profile. In early RA patients initiating adalimumab combination therapy, efficacy of 10 and 20mg/week MTX appeared equivalent.
引用
收藏
页码:1037 / 1044
页数:8
相关论文
共 34 条
[1]   Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components [J].
Aletaha, Daniel ;
Smolen, Josef ;
Ward, Michael M. .
ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2784-2792
[2]   2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].
Aletaha, Daniel ;
Neogi, Tuhina ;
Silman, Alan J. ;
Funovits, Julia ;
Felson, David T. ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Kvien, Tore K. ;
Laing, Timothy ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Naden, Raymond L. ;
Pincus, Theodore ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581
[3]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[4]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[5]   Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis [J].
Braun, J. ;
Kaestner, P. ;
Flaxenberg, P. ;
Waehrisch, J. ;
Hanke, P. ;
Demary, W. ;
von Hinueber, U. ;
Rockwitz, K. ;
Heitz, W. ;
Pichlmeier, U. ;
Guimbal-Schmolck, C. ;
Brandt, A. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :73-81
[6]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[7]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[8]   Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis [J].
Cronstein, BN .
PHARMACOLOGICAL REVIEWS, 2005, 57 (02) :163-172
[9]  
Cutolo M, 2000, J RHEUMATOL, V27, P2551
[10]   Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study [J].
Detert, Jacqueline ;
Bastian, Hans ;
Listing, Joachim ;
Weiss, Anja ;
Wassenberg, Siegfried ;
Liebhaber, Anke ;
Rockwitz, Karin ;
Alten, Rieke ;
Krueger, Klaus ;
Rau, Rolf ;
Simon, Christina ;
Gremmelsbacher, Eva ;
Braun, Tanja ;
Marsmann, Bettina ;
Hoehne-Zimmer, Vera ;
Egerer, Karl ;
Buttgereit, Frank ;
Burmester, Gerd-R .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (06) :844-850